Pfizer Inc.  

(Public, NYSE:PFE)   Watch this stock  
23.81
-0.01 (-0.04%)
Real-time:   9:59AM EDT
NYSE real-time data - Disclaimer
Currency in USD
Range 23.73 - 23.95
52 week 16.63 - 24.49
Open 23.92
Vol / Avg. 5.97M/36.32M
Mkt cap 178.29B
P/E 20.68
Div/yield 0.22/3.70
EPS 1.15
Shares 7.49B
Beta 0.69
Inst. own 72%
Jul 31, 2012
Q2 2012 Pfizer Earnings Conference Call
Jul 12, 2012
Verastem Inc Research and Development Day and discussion of acquisition of Clinical-Stage FAK Inhibitor from Pfizer - Webcast
Jun 3, 2012
Pfizer at American Society of Clinical Oncology Annual Meeting - Webcast
May 17, 2012
Pfizer at Bank of America Merrill Lynch Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Jul '12) 2011
Net profit margin 21.21% 12.96%
Operating margin 29.78% 18.93%
EBITD margin - 34.13%
Return on average assets - 4.56%
Return on average equity - 10.24%
Employees 103,700 -
Carbon Disclosure Rating - 81/100

Address

235 East 42nd Street
NEW YORK, NY 10017-5755
United States - Map
+1-212-7332323 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia
Discussion Group - Google Finance

Description

Pfizer Inc. (Pfizer) is a research-based, global biopharmaceutical company. The Company manages its operations through five segments: Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; Animal Health and Consumer Healthcare, and Nutrition. The Company�s diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and consumer healthcare products. Its Animal Health business unit discovers, develops and sells products for the prevention and treatment of diseases in livestock and companion animals. On August 1, 2011, it completed the sale of its Capsugel business. In October 2011, it acquired Icagen, Inc. In December 2011, it acquired the consumer healthcare business of Ferrosan Holding A/S. In December 2011, it acquired Excaliard Pharmaceuticals, Inc.

Officers and directors

Ian C. Read Chairman of the Board, President, Chief Executive Officer
Age: 58
Bio & Compensation - Reuters
Frank A. D'Amelio Chief Financial Officer, Executive Vice President - Business Operations
Age: 54
Bio & Compensation - Reuters
Mikael Dolsten M.D., Ph.D. President - Worldwide Research and Development
Age: 53
Bio & Compensation - Reuters
Cavan M. Redmond Group President - Animal Health, Consumer Healthcare and Corporate Strategy
Age: 51
Bio & Compensation - Reuters
Douglas M. Lankler Executive Vice President, Chief Compliance and Risk Officer
Age: 46
Bio & Compensation - Reuters
Amy W. Schulman Executive Vice President, General Counsel, President and General Manager - Nutrition
Age: 51
Bio & Compensation - Reuters
Charles H. Hill III Executive Vice President - Worldwide Human Resources
Age: 56
Bio & Compensation - Reuters
Freda C. Lewis-Hall M.D. Executive Vice President, Chief Medical Officer
Age: 57
Bio & Compensation - Reuters
Laurie Olson Executive Vice President - Strategy, Portfolio Management and Global Commercial Operations
Bio & Compensation - Reuters
Kristin C. Peck Executive Vice President - Worldwide Business Development and Innovation
Age: 40
Bio & Compensation - Reuters